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Summary
Dihydropyrimidinase (DHP) deficiency (MIM 222748)
is characterized by dihydropyrimidinuria and is associ-
ated with a variable clinical phenotype. This disease
might be associated with a risk of 5-fluorouracil toxicity,
although no cases have been reported. We present here
both the molecular characterization of the human DHP
gene and, for the first time, the mutations causing DHP
deficiency. The human DHP gene spans 180 kb and con-
sists of 10 exons. It has been assigned to 8q22, by FISH.
We performed mutation analysis of genomic DNA in
one symptomatic and five asymptomatic individuals pre-
senting with dihydropyrimidinuria. We identified one
frameshift mutation and five missense mutations. Two
related Japanese adult subjects were homozygous for the
Q334R substitution, whereas two other, unrelated Jap-
anese infant subjects were heterozygous for the same
mutation, but this mutation is not common in the Jap-
anese population. A Caucasian pediatric patient exhib-
iting epileptic attacks, dysmorphic features, and severe
developmental delay was homozygous for W360R. Us-
ing a eukaryotic expression system, we showed that all
mutations reduced enzyme activity significantly, indi-
cating that these are crucial DHP deficiency–causingmu-
tations. There was no significant difference, in residual
activity, between mutations observed in the symptomatic
and those observed in the asymptomatic individuals.
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Introduction
Dihydropyrimidinase (DHP [E.C.3.5.2.2]) is the second
enzyme in the three-step degradation pathway of uracil
and thymine. DHP catalyzes the reversible hydrolysis of
dihydrouracil to N-carbamyl-b-alanine and of dihydro-
thymine to N-carbamyl-b-aminoisobutyric acid (Fritz-
son 1957; Fritzson and Phil 1957). DHP is a homotet-
rameric metalloenzyme, containing four tightly bound
zinc ions per molecule of active enzyme (Brooks et al.
1979, 1983; Kikugawa et al. 1994). Purified DHP from
rat liver has a molecular mass of 215 kD and a subunit
mass of 54 kD (Kikugawa et al. 1994). We isolated
cDNA clones encoding DHP from human and rat liver,
which contained 1,560-bp open reading frames encoding
polypeptides of 519 residues (Hamajima et al. 1996;
Matsuda et al. 1996). Moreover, we isolated three ho-
mologous cDNA clones from human fetal brain, which
we named “DHP related proteins” (DRPs) and thus
identified a novel gene family defined by DHP and DRPs
with differential tissue distribution (Hamajima et al.
1996).
DHP deficiency (MIM 222748) is thought to be an
autosomal recessive disorder that is characterized by di-
hydropyrimidinuria and associated with a variable clin-
ical phenotype. DHP deficiency might be associatedwith
the pharmacogenetic syndrome of 5-fluorouracil (5-FU)
toxicity (Hayashi et al. 1996), although no cases have
been reported. To date, nine cases of dihydropyrimidi-
nuria have been reported. Four unrelated cases showed
variable clinical symptoms: epileptic or convulsive at-
tacks (Duran et al. 1990; Henderson et al. 1993; Van
Gennip et al. 1997b), dysmorphic features and severe
developmental delay (Henderson et al. 1993; Van Gen-
nip et al. 1997b), and congenital microvillous atrophy
(Assmann et al. 1997). However, the relationship be-
tween these symptoms and the enzyme defect has not
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Figure 1 Schematic representation of genomic and mRNA structure of human DHP. A, Structure of human DHP mRNA (Hamajima et
al. 1996). Diagonally hatched and unmarked boxes represent coding and noncoding regions, respectively, arrows indicate the probe-covering
regions. B, Structure and restriction map of human DHP gene. Exons are denoted by thick vertical rules (exons 1 and 10) and thin vertical
lines (exon 2–9) on the “Genomic DNA” line, EcoRI sites are indicated by the vertical tic marks on the “EcoRI site” line, and isolated phage
clones containing genomic DNA fragments encoding the human DHP gene are shown below the “EcoRI site” line.
been elucidated. On the other hand, three unrelated in-
fant and two related adult cases without clinical symp-
toms were discovered by a program screening for py-
rimidine-degradation disorders in a healthy Japanese
population (Ohba et al. 1994; Sumi et al., in press). The
population study based on this screening program re-
vealed a relative high frequency of this condition, of
0.1% (2:20,000), in the Japanese population (Sumi et
al., in press). In only two cases, DHP deficiency was
enzymatically confirmed by direct measurement of liver
DHP activity (Assmann et al. 1997; Van Gennip et al.
1997b). In the present article we describe both the mo-
lecular characterization of the human DHP gene and,
for the first time, mutations causing DHP deficiency,
which are identified by molecular analysis of genomic
DNA in one symptomatic and five asymptomatic indi-
viduals presenting with dihydropyrimidinuria.
Subjects, Material, and Methods
Subjects
Asymptomatic subjects 1 and 4 (females) and subject
5 (male) were unrelated and had been born to healthy
nonconsanguineous Japanese parents. These subjects
were identified at age 6–12 mo, in a program that
screened for inborn errors of pyrimidine metabolism and
that was operated as a pilot study (Ohba et al. 1994;
Sumi et al., in press). Subject 2 was an adult male and
had been born to healthy nonconsanguineous Japanese
parents. He had no clinical symptoms and had been
discovered, at age 37 years, by a screening program
(Hayashi et al. 1996; Sumi et al., 1996). Subject 3 was
an adult female and a younger sister of subject 2. She
had no clinical symptoms and had been discovered, at
age 36 years, in a study of the family of subject 2 (Sumi
et al., in press). Subject 6 was an infant female born to
a consanguineous couple from Lebanon, who exhibits
dysmorphic features, severe developmental delay, and
convulsions (Van Gennip et al. 1997b). In this case, DHP
deficiency was confirmed enzymatically, by direct mea-
surement of liver DHP activity. All subjects showed the
characteristic biochemical abnormalities observed in
DHP deficiency, including elevated concentrations of
dihydrouracil, dihydrothymine, uracil, and thymine in
their bodily fluids.
Isolation of Genomic Clones
Three DNA fragments, of 878, 903, and 329 bp, were
prepared by PstI and BamHI digestion of a plasmid
DNA containing the human DHP cDNA and were used
as probes 1, 2, and 3, respectively, for screening of a l-
EMBL3 human genomic DNA library (Japanese Cancer
Research Resources Bank) (fig. 1). Two DNA fragments,
of 367 and 429 bp, were prepared by PCR and were
used as probes 4 and 5, respectively, for screening of a
l-FIX II human genomic DNA library (Stratagene) (fig.
1). The latter PCR reactions were performed with the
plasmid DNA containing the human DHP cDNA as a
template, with sense primer 5′-GGC TGT CGG TGG
GGA CCT TG-3′ and antisense primer 5′-GGT GCC
CTG GTT GGA AGT TCG T-3′, for probe 4, and with
sense primer 5′-GAA GGT GGT CTA TGG TGA AC-
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Table 1
PCR Primers to Amplify Exons of the Human DHP Gene
Exon
Primera
(5′r3′ )
Product
Length
(bp)Sense Antisense
1 TGCAGGAGGGCACCCCAAGC gaggcggccctgctgaggac 461
2 atgcccttctgggtcattta tctgtcctcctgttgtgtag 423
3 gagcagcagcagtttatcag gcccaatcatcttcacctta 454
4 gatcaaaagcctggcattgc ctcctaaactgaagcagagg 376
5 tatctggtagggttttggag ggatcctggctgaagaacta 532
6 gagacaggagagggatgaaa ggatcctggctgaagaacta 362
7 catcctcagatgctctacaa ctacatcctctatgccaaga 476
8 tcaagtgagctggtgatgat ggaaatcccgaactgaccta 549
9 cacaaaaagtgggacaatcc gtgaagcctctgaccttgat 421
a Exon and intron sequences are denoted by uppercase and lowercase letters,
respectively.
3′ and antisense primer 5′-GGG TCC CAA ATA ACA
ATGTC-3′, for probe 5. Probes were labeled witha[32P]-
dCTP, with the aid of a Rediprime DNA-labeling system
(Amersham), and were used to screen ∼1# 106 plaques
from each human genomic DNA library. Positive clones
were analyzed by restriction-enzyme mapping and
Southern blotting. Exon-containing DNA fragments
were subcloned into pGEM-3Zf() vector and were se-
quenced by a 373A DNA sequencer (Applied Biosys-
tems), to analyze each exon/intron boundary. Each in-
tron size was determined by PCR, except for introns 7
and 8.
FISH
FISH of 5-bromodeoxyuridine–synchronized human
metaphase chromosomes was performed as described
elsewhere (Takeda et al. 1993), with use of EcoRI frag-
ments of genomic DNA of the human DHP gene as
probes. The biotin-labeled DNA probes were hybridized
to metaphase spreads under conditions that suppressed
signals from repetitive DNA sequences. After fluoro-
chrome detection with FITC-conjugated avidin DCS
(Vector Laboratories) and biotin-conjugated goat anti–
avidin D antibody (Vector Laboratories), the prepara-
tions were counterstained with propidium iodide and
were examined by a laser scanning microscope (Zeiss
LSM).
Analysis of Genomic DNA
Genomic DNA was prepared from peripheral blood
leukocytes of subjects 1–6 and selected members of their
families, by phenol-chloroform extraction. PCR primers
were designed, by use of exon and intron sequences, to
amplify the genomic region containing exons 1–9 (table
1). Exon amplification was performed by the following
program: 10 min at 95C, followed by 30 cycles (for
exon 1, 35–40 cycles) of 30 s at 95C, 1 min at 55C,
and 1 min at 72C (for exon 1, 1 min at 96C, 1 min
at 64C, and 1 min at 72C). The resulting amplification
products were subcloned into a pCR2.1 vector (Invitro-
gen), and at least eight independent clones were se-
quenced for each exon, by a 373A DNA sequencer (Ap-
plied Biosystems). Both strands of each sequence were
determined.
PCR-RFLP Analysis
Since the A1001G transition (Q334R) in exon 6 cre-
ates a recognition site for MspI (CCAGrCCGG), PCR-
RFLP analysis to detect this mutation was performed for
family and population studies. Peripheral leukocyte ge-
nomic DNA was isolated from 100 unrelated healthy
Japanese volunteers and was subjected to the PCR-RFLP
analysis. The resulting 362-bp exon 6 amplification
products were digested by MspI and were analyzed by
electrophoresis in a 2% agarose gel. Mutant alleles were
identified on the basis of a digestion pattern showing a
217- and a 145-bp band, whereas wild-type alleles
showed only the undigested, 362-bp band.
SSCP
Since the T1078C transition (W360R) in exon 6
causes no change in the restriction-enzyme site, SSCP
analysis of exon 6 was performed for family and pop-
ulation studies. Control DNA samples for population
studies were obtained from Dutch newborn-screening
cards (∼95% Caucasian). Amplification of the genomic
region containing exon 6 was performed in a 10-ml re-
action containing 20–50 ng genomic DNA; 10 mMTris/
HCl (pH 8.3); 50 mM KCl; 2.5 mM MgCl2; 30 ng each
of sense primer (5′-CAC CCC ATC ACT CTC GTG T-
3′) and antisense primer (5′-GGA TCC TGG CTG AAG
AAC TA-3′); 2.5 mM each of dCTP, dTTP, and dGTP
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(Pharmacia); 0.25 mM dATP; 0.1 mCi a[32P]-dATP
(Amersham); and 1 U Taq polymerase (Perkin Elmer).
The amplification reaction was performed for 35 cycles
(30 s at 95C, 1 min at 55C, and 1 min at 72C). The
225-bp amplification products were diluted 1:20 in 10
mM EDTA, 0.01% SDS and subsequently were diluted
1:4 in layer mix (2 mM EDTA in formamide). Samples
were denatured for 3 min at 94C and were cooled, at
the rate of 1C/s, to 4C. Finally, the samples were an-
alyzed on a 8% polyacrylamide (mono:bis 49:1), 5%
glycerol gel running for 16 h at 8 W (at room
temperature).
Expression-Plasmid Construction and Transfection
An expression plasmid containing the wild-type hu-
man DHP cDNA (pCR3-hDHP-WT) was constructed
by subcloning the insert of a plasmid containing the
complete coding region of the human DHP cDNA into
eukaryotic expression vector pCR3 (Invitrogen). Ex-
pression plasmids containing the mutant human DHP
cDNA (pCR3-hDHP-T68R, pCR3-hDHP-InsA, pCR3-
hDHP-Q334R, pCR3-hDHP-W360R, pCR3-hDHP-
G435R, and pCR3-hDHP-R490T) were constructed by
subcloning the site-directed mutagenesis products for
each mutation into pCR3-hDHP-WT. The resulting sub-
clones were analyzed, by sequence analysis, to verify the
introduction of the desired mutation and to exclude the
presence of artifactually introduced changes. All ex-
pression plasmids were purified by means of a plasmid
midi kit (QUIAGEN). Transfection into COS-7 cells was
performed in 10-cm dishes, with 3 ml of opti-MEM
medium (GIBCO-BRL) containing 4 mg of each expres-
sion plasmid, 30 ml lipofectamine (2 mg/ml), and 20 ml
lipofectamine plus. To normalize for any variability in
transfection efficiency, 0.5 mg pSV-bGal (Promega), an
expression plasmid containing the Escherichia coli b-
galactosidase cDNA, was cotransfected as an internal
standard. Mock transfection was performed by use of
self-ligated pCR3 vector and pSV-bGal.
Enzyme-Activity Assay
Cell extracts were made 24 h after the transfection,
by use of 1# reporter lysis buffer (Promega). The level
of exogenous DHP in COS-7 cells transfected with wild-
type or mutant expression plasmids was determined by
measurement of the decrease of absorbance at 225 nm,
by use of 20 mM 5-bromo-dihydrouracil as a substrate
and 30 ml cell extracts in 50 mM Tris-HCl (pH 8.2) at
37C for 30 min, essentially as described by Kikugawa
et al. (1994). The level of exogenous b-galactosidase in
COS-7 cells transfected with pSV-bGal was determined
using a b-galactosidase enzyme assay system (Promega).
Protein concentrations were determined by a bicinchon-
inic acid protein–assay reagent (Pierce), with bovine se-
rum albumin used as a standard. The measurement of
absorbance was performed by a DU-640 spectropho-
tometer (Beckman). The activities in COS-7 cells trans-
fected with the mutant constructs were expressed as the
percentage of DHP activity determined in the cells trans-
fected with wild-type expression plasmid after both sub-
traction of the endogenous activity and normalization
by b-galactosidase activity. Statistical analysis was per-
formed by the Mann-Whitney U-test.
Western Blot Analysis
Aliquots of 5–17 mg protein isolated from cell extracts,
quantitatively normalized for differences in b-galacto-
sidase activity, were subjected to 10% SDS-PAGE and
were transferred to a nitrocellulose filter. Western blot
analysis was performed with 1:750-diluted anti–rat liver
DHP polyclonal antibody. Protein detection was per-
formed by treatment with 1:3,000-diluted horseradish
peroxidase–conjugated goat anti–rabbit IgG antibody
(BIO-RAD), followed by staining with HRP color rea-
gent (BIO-RAD).
Northern Blot Analysis
Total RNA from transfected COS-7 cells was ex-
tracted by use of ISOGEN (Nippongene). In each lane,
5 mg total RNA was separated on a 1% agarose gel, was
blotted onto a Hybond-N nylon membrane (Am-
ersham), and subsequently was hybridized with a[32P]-
dCTP–labeled probe 1 (see Isolation of Genomic Clones
subsection [above]) and the insert of pSV-bGal, by stan-
dard procedures.
Results
Isolation and Characterization of the Human DHP
Gene
Screening of the l-EMBL3 human genomic library
with probes 1, 2, and 3 (see Subjects, Material, and
Methods section [above]) yielded 4, 1, and 7 positive
clones, respectively. These phage clones were analyzed
by restriction-enzyme mapping and Southern blotting
(fig. 1). To isolate the genomic clones containing the
remaining exons, the screening of a l-FIX II human ge-
nomic library with probes 4 and 5 was performed, re-
sulting in 8 and 4 positive clones, respectively (fig. 1).
The human DHP gene was found to span 180 kb and
contained 10 exons with lengths of 131–420 bp. Nu-
cleotide-sequence data for exon/intron boundaries
showed that all introns contained the conserved 5′-GT
splice donor and 3′-AG splice acceptor sites (table 2).
(The nucleotide-sequence data reported in this article
have been submitted to the Genbank database, with ac-
cession numbers AB004669–AB004678 for exons 1–10,
respectively.) Comparison of the human DHP genomic
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Table 2
Exon/Intron Boundaries of the Human DHP Gene
Exon (Size [bp])
cDNA Position
of Exona Donor Siteb Intron (Size [kb]) Acceptor Siteb
1 (393) 129 to 264 GGGCACCAAG gt acccgccc 1 (12.0) atgattcc ag GCTGCTCTCT
2 (159) 265 to 423 GAGTGACCAG gt aaagcacc 2 (5.0) ttcctttt ag GTTAAAGAAG
3 (180) 424 to 603 AATTGCAGAG gt acgcattt 3 (3.0) gtcttttt ag GGAGCAAAGA
4 (190) 604 to 793 AGGAGAGATG gt aattctcg 4 (15.0) atctttcc ag GGAAGGTGGT
5 (157) 794 to 950 TGTTGGCTAA gt aatcattt 5 (1.5) tcttttac ag TGATGATCTA
6 (142) 951 to 1092 AAAAGGCGTG gt gggtttca 6 (10.0) tgctttac ag CATAGTGGTA
7 (143) 1093 to 1235 AAGGCACAAG gt aagtctaa 7 (120.0) acaaatat ag GACTATCTCA
8 (208) 1236 to 1443 GCGAGACCGG gt gagtgtgc 8 (15.5) tctctttc ag ACTTGCACAC
9 (131) 1444 to 1574 TGTGCCATCG gt aagggact 9 (1.0) ctcttcaa ag GTAAAAAAAA
10 (420) 1575 to 1994
a Nucleotides are numbered according to the cDNA sequence, starting with 1 for the first nucleotide of the initiation
codon. The transcription initiation site was determined by 5′ rapid amplification of the cDNA end and by ribonuclease-
protection assay (data not shown).
b Exon and intron sequences are denoted by uppercase and lowercase letters, respectively, and the nucleotide consensus
sequence of the introns adjoining the splice junctions is underlined.
Figure 2 Chromosomal localization of DHP gene on R-banded human chromosomes. Specific FITC signals in the region of chromosome
8q22 are indicated by arrows (A–C). A schematic presentation of human chromosome 8 and of the location of the DHP gene is shown on the
right.
sequence with a cDNA sequence reported elsewhere (Ha-
majima et al. 1996) revealed no differences in the coding
region. Southern blot analysis of total human genomic
DNA restriction fragments showed that this gene exists
as a single copy (data not shown).
Chromosomal Localization of the Human DHP Gene
Specific FISH signals generated from biotinylated ge-
nomic DNA of the DHP gene were observed on the long
arm of human chromosome 8, in the majority of the
metaphase spreads examined (fig. 2). No other repro-
ducible signal was observed on metaphase chromo-
somes. Thus, FISH assigned the human DHP gene to
8q22.
Mutation Analysis of Genomic DNA
Sequence analysis of exons 1–9 was performed by use
of genomic DNA from subjects 1–6, resulting in the
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Table 3
Genotype of the Human DHP Gene in DHP-Deficient Patients
Family Subject Genotype Effecta
1 1 A1001G/Insertion Ab Q334R/Frameshiftb
2 2 A1001G/A1001G Q334R/Q334R
3 A1001G/A1001G Q334R/Q334R
3 4 A1001G/G1303Ac Q334R/G435Rc
4 5 G203C/C1468G T68R/R490T
5 6 T1078C/T1078C W360R/W360R
a On DHP protein or mRNA.
b Single-base insertion of A at nucleotide position 812 to
814, leading to a frameshift from codon 272 and to a premature
termination of translation at codon 287.
c Whether Q334R and G435R are actually on the different
alleles in this subject could not be definitively determined.
Figure 3 PCR-RFLP analysis to detect Q334R mutant alleles. Partial pedigrees of families 1–3, as well as the results of MspI digestion
of PCR products, are shown. The 362-bp PCR products of exon 6 were digested with MspI and were analyzed on a 2% agarose gel. In the
presence of the A1001G transition (Q334R), MspI digestion generates two fragments, of 217 and 145 bp. Lane M, Molecular size marker.
Lane 1, Subject 1. Lane 2, Mother of subject 1, Lane 3, Father of subject 1. Lane 4, Subject 2. Lane 5, Wife of subject 2. Lane 6, Child 1 of
subject 2. Lane 7, Child 2 of subject 2. Lane 8, Subject 3. Lane 9, Mother of subjects 2 and 3. Lane 10, Father of subjects 2 and 3. Lane 11,
Subject 4. Lane 12, Sibling of subject 4. Lane 13, Mother of subject 4. Lane C, Normal control. A plus sign () denotes that the individual is
positive for the MspI site, and a minus sign () denotes that the individual is negative for the MspI site.
identification of one frameshift mutation and five mis-
sense mutations (table 3). Subjects 2 and 3 were shown
to be homozygous for an A1001G (Q334R) transition
in exon 6, whereas subjects 1 and 4 were shown to be
heterozygous for the same mutation. Since the A1001G
transition creates a recognition site forMspI, PCR-RFLP
analysis to detect this mutation was performed in sub-
jects 1–3 and their family members (fig. 3). The ampli-
fication products from subjects 2 and 3 were digested
completely by MspI and showed 217- and 145-bp frag-
ments, indicating homozygosity for this mutation. Sub-
ject 1 and her mother, two children of subject 2, both
parents of both subject 2 and subject 3, and subject 4
and her mother showed the 362-, 217-, and 145-bp frag-
ments, consistent with heterozygosity for this mutation.
Subject 1 was also shown to be heterozygous for a single-
base insertion at nucleotide positions 812–814 (InsA) in
exon 5. This insertion leads to a frameshift at codon
272 and causes premature termination of translation at
codon 287. Since the father of subject 1 was found to
be a heterozygote for InsA (data not shown), subject 1
was confirmed to be a compound heterozygote for
Q334R and InsA. Subject 4 was shown to be hetero-
zygous for a G1303A transition (G435R) in exon 8;
however, this mutation was not identified in either her
mother or her sibling. Since her father was not available
for any biochemical or molecular analysis, and since we
did not succeed in a long PCR using genomic DNA from
patient 4 to amplify exons 6–8 at a stretch, we could
not strictly determine whether Q334R and G435R are
actually on the different alleles in subject 4, although it
seems likely that subject 4 is indeed a compound het-
erozygote for both Q334R and G435R. Subject 5 was
shown to be a heterozygote for a G203C transition
(T68R) in exon 1 and for a G1468C transition (R490T)
in exon 9. The mother was shown to be heterozygous
for R490T, whereas the father was shown to be heterozy-
gous for T68R. Therefore, subject 5 was confirmed to
be a compound heterozygote for both T68R and R490T.
Finally, subject 6 was shown to be homozygous for a
T1078C transition (W360R) in exon 6. Since this mu-
tation causes no change in restriction-enzyme site, an
SSCP analysis of the exon 6 PCR fragment was per-
formed on subject 6 and her family members. SSCP anal-
ysis showed that both the (consanguineous) parents and
the maternal grandfather were heterozygous for this mu-
tation (fig. 4).
Population Study of Q334R and W360R
In order to establish the frequency of the Q334R and
W360R mutation, either PCR-RFLP analysis (in the case
of Q334R) or SSCP analysis (in the case of W360R) was
performed on 100 unrelated Japanese and 200 Cauca-
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Figure 4 SSCP analysis of exon 6. SSCP analysis of case 6 and
her family members was performed as described in the Subjects, Ma-
terial, and Methods section. Lane 1, Subject 6. Lane 2, Father. Lane
3, Mother. Lane 4, Maternal grandfather. Lane 5, Maternal grand-
mother. Note that the case is homozygous for C1078, whereas the
father, mother, and maternal grandfather are heterozygous. The ma-
ternal grandmother has two normal T1078 alleles. Results were con-
firmed by sequence analysis.
Figure 5 Western blot analysis of cell extracts from COS-7 cells
transfected with wild-type and mutant expression plasmids. Each lane
contains 10–17 mg cell extracts, quantitatively normalized for b-gal-
actosidase activity and hybridized with polyclonal antibody to rat liver
DHP. COS-7 cells were transfected with either pCR3 and pSV-bGal
(Mock), pCR3-hDHP-WT and pSV-bGal (WT), pCR3-hDHP-T68R
and pSV-bGal (T68R), pCR3-hDHP-InsA and pSV-bGal (InsA), pCR3-
hDHP-Q334R and pSV-bGal (Q334R), pCR3-hDHP-W360R and
pSV-bGal (W360R), pCR3-hDHP-G435R and pSV-bGal (G435R), or
pCR3-hDHP-R490T and pSV-bGal (R490T).
sian control samples, respectively. The PCR-RFLP anal-
ysis to detect Q334R revealed no carriers of this mu-
tation (data not shown), suggesting that Q334R is not
common in the Japanese population; the SSCP analysis
to detect W360R did also not reveal any mutant allele
(data not shown), suggesting that W360R is not com-
mon in the Caucasian population.
Expression Analysis of Mutated Alleles
In order to establish whether the identified mutations
are responsible for the DHP-deficient phenotype, these
mutations were introduced into pCR3-hDHP-WT ex-
pression plasmid by site-directed mutagenesis and sub-
sequently were expressed transiently in COS-7 cells. Al-
though endogenous DHP activity could be detected in
mock-transfected COS-7 cells (mean SD  0.365
nmol/min/mg protein; ), expression of0.045 n  6
pCR3-hDHP-WT resulted in an ∼24-fold induction of
DHP activity ( nmol/min/mg protein;8.625 0.187
), similar to the activity reported for the rat livern  6
enzyme (Kikugawa et al. 1994). The (mean SD n 
) activities in COS-7 cells transfected with the6
mutant constructs pCR3-hDHP-T68R, pCR3-hDHP-
InsA, pCR3-hDHP-Q334R, pCR3-hDHP-W360R,
pCR3-hDHP-G435R, and pCR3-hDHP-R490T were
, ,1.493% 0.589% 1.355% 0.440% 2.511%
, , , and0.963% 1.155% 0.747% 5.114% 0.871%
, respectively, of the exogenous ac-1.711% 0.444%
tivity in pCR3-hDHP-WT–transfected COS-7 cells.
These results imply that all mutant plasmid–transfected
COS-7 cells exhibited a severe reduction of enzymatic
activity ( ). However, the activity observed inP ! .005
pCR3-hDHP-G435R–transfected COS-7 cells was sig-
nificantly higher than that in the other mutant plas-
mid–transfected COS-7 cells ( ). Expression ofP ! .005
wild-type and mutant plasmid–transfected COS-7 cells
was further investigated, by western and northern
blot analysis. Western blot analysis revealed a significant
reduction of DHP immunostainable protein in the
pCR3-hDHP-InsA–, pCR3-hDHP-W360R–, and pCR3-
hDHP-G435R–transfected COS-7 cells, suggesting that
the stability or biosynthesis of these mutant proteins is
reduced (fig. 5). Other mutant plasmids (pCR3-hDHP-
T68R, pCR3-hDHP-Q334R, and pCR3-hDHP-R490T)
expressed equal amounts of DHP immunostainable pro-
tein, compared with the wild-type construct. By contrast,
northern blot analysis showed no significant reduction
of DHP mRNA expression for any mutant plasmid–
transfected COS-7 cells, indicating that all mutant DHP
mRNAs are properly transcribed, processed, and equally
stable (fig. 6).
Discussion
In this article we have described the genomic structure
of the DHP gene and have shown unequivocally that
mutations in this gene provide the molecular basis for
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Figure 6 Northern blot analysis of total RNA from COS-7 cells
transfected with wild-type and mutant expression plasmids. Each lane
contains 5 mg total RNA hybridized with human DHP cDNA (upper
panel) and E. coli b-galactosidase cDNA (lower panel). COS-7 cells
were transfected with either pCR3 and pSV-bGal (Mock), pCR3-
hDHP-WT and pSV-bGal (WT), pCR3-hDHP-T68R and pSV-bGal
(T68R), pCR3-hDHP-InsA and pSV-bGal (InsA), pCR3-hDHP-
Q334R and pSV-bGal (Q334R), pCR3-hDHP-W360R and pSV-bGal
(W360R), pCR3-hDHP-G435R and pSV-bGal (G435R), or pCR3-
hDHP-R490T and pSV-bGal (R490T).
human DHP deficiency. Since DHP is expressed only in
liver and kidney, enzymatic confirmation of this defect
has been performed in only two symptomatic patients.
The elucidation of the genomic structure of the DHP
gene provides a tool for confirmation of DHP deficiency,
without the need to take a liver or kidney biopsy. In
addition, molecular analysis of the DHP gene allows
unequivocal detection of heterozygotes, which is not
possible by means of conventional metabolic analysis.
The human DHP gene has been assigned to 8q22, by
FISH (fig. 2). This locus also has been recognized as one
of the common fragile sites and is recombinogenic in
several human malignancies (Wood et al. 1993). More-
over, there are several disorders associated with abnor-
malities of this locus, including Cohen syndrome (Tah-
vanainen et al. 1994), congenital diaphragmatic hernia
(Temple et al. 1994), and cleidocranial dysplasia (Brue-
ton et al. 1992). It would be interesting to investigate a
possible relationship between these disorders and the
DHP gene.
Mutation analysis of genomic DNA in six DHP-de-
ficient individuals revealed the presence of one frameshift
mutation (InsA) and five missense mutations (T68R,
Q334R,W360R, G435R, and R490T). Expression anal-
ysis of these mutations in COS-7 cells revealed that all
of them exhibit severely reduced enzymatic activity, in-
dicating that they are DHP deficiency–causing muta-
tions, although the possibility of allelic interactions in
the compound-heterozygous genotypes observed in sub-
jects 1, 4, and 5 remained to be examined. Except for
subject 4, all subjects were found to be either homo-
zygous or compound heterozygous for one or two of
these mutations and were diagnosed as definitely DHP
deficient at the molecular genetic level. Although we
could not determine whether Q334R and G435R were
on different alleles in subject 4, it is likely that this sub-
ject is a compound heterozygote. Further evidence is pro-
vided by the detailed chemical analysis of pyrimidine
metabolites in the urine of this patient and of her avail-
able family members (Sumi et al., in press).
Three mutant proteins (InsA, W360R, and G435R)
were expressed in COS-7 cells only at low levels, as
judged on the basis of western blot analysis. This re-
duction could not be due to either reduced transcription
rates or mRNA instability, since the mutant mRNAs
were expressed at levels equal to those in the wild-type
and other mutant constructs. However, since the InsA
frameshift mutation leads to a premature termination of
translation at codon 287, it is likely that the truncated
translation product is either unstable or no longer rec-
ognized by the antibody. In addition, reduced protein
stability also has been observed in other proteins con-
taining nonsense or missense mutations (Zhang et al.
1996; Hovnanian et al. 1997). The mutation W360R is
located at the amino-terminal end of the strongly con-
served region in DHP and DHP-related proteins (DRPs)
(Hamajima et al. 1996), and this region recently has been
shown to be essential to in vitro heterotetramer for-
mation of DRPs (Wang and Strittmatter 1997). More-
over, WD (i.e., Trp-Asp) or WE (i.e., Trp-Glu) repeats,
which are implicated in protein-protein interactions in
GTP-binding protein (Neer et al. 1994), are observed in
this region of DHP and DRP sequences. The amino acid
residuesWE, at codons 360 and 361, andWD, at codons
406 and 407, in the DHP sequence also may be essential
to homotetramer formation of this enzyme. Therefore,
the W360R substitution may prevent tetramerization,
causing instability of the subunit. By contrast, the
G435R mutant protein showed significantly higher ac-
tivity than was seen in other mutant proteins, despite a
reduced steady-state protein level. Gly at codon 435may
be essential to protein stability but not important for
catalytic activity of the enzyme. To ascertain whether
the reduced steady-state level of these mutant proteins
is really due to protein instability, pulse-chase experi-
ments are in progress.
The putative zinc-binding sites of DHP are believed
to be located either at His67, His69, and His132 (Mat-
suda et al. 1996) or at His67, His69, His192, and
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His248 and Asp326 (Holm and Sander 1997). The
T68R substitution is located between His67 and His69
and may result in the inability to bind a zinc ion. The
Q334R substitution is located in the vicinity of Asp326
and also may influence the zinc ion–binding ability. In
addition, three substitutions (T68R, Q334R, and
R490T) are located at completely conserved residues in
human and rat DHP and in mammalian or avian DRPs.
Substitutions at these residues may alter the secondary
or tertiary structure of this enzyme or may influence the
ability to bind to substrates, without affecting protein
stability.
Only one of the DHP-deficient subjects described here
(i.e., subject 6) shows a clinical phenotype, whereas all
other subjects are asymptomatic. The observation that
deficiencies in enzymes involved in pyrimidine degra-
dation are not always correlated with a clinical phe-
notype also has been recognized in dihydropyrimidine
dehydrogenase (DPD) deficiency. Moreover, it has been
shown that, within a single family, identical DPD geno-
types do not necessarily lead to identical phenotypes,
indicating a lack of correlation between phenotype and
genotype (Fernandez-Salguero et al. 1997; Vreken et al.
1997a, 1997b, 1997c). The present study has provided
evidence that molecular defects in the DHP gene, re-
sulting in functional DHP deficiency as judged on the
basis of the accumulation of pyrimidine degradation
products in bodily fluids of these patients, also do not
necessarily lead to a clinical phenotype. Decreased syn-
thesis of the neurotransmitter b-alanine may play a role
in the neurological symptoms observed in symptomatic
DHP- and DPD-deficient patients (Van Gennip et al.
1997a), although the presence of a clinical phenotype is
unlikely to be solely dependent on b-alanine homeosta-
sis. We cannot exclude the possibility that the pheno-
types in the symptomatic DHP- and DPD-deficient pa-
tients, rather than being due to these enzyme defects,
are only coincidentally associated with the genotypes of
these patients. It is tempting, however, to speculate that
DHP is a multifunctional protein and serves other func-
tions common to the DRPs. Homozygosity for protein-
reducing mutations is not identified in asymptomatic
DHP-deficient subjects. The multifunctionality of the
DHP protein may be responsible for the phenotype ob-
served in subject 6. Further biochemical and molecular
studies are needed in order to elucidate this point.
Similar to the increased toxicity observed in homo-
zygous and heterozygous DPD-deficient individuals (Wei
et al. 1996; Van Kuilenburg et al. 1997), homozygosity
for DHP deficiency is likely to cause increased 5-FU tox-
icity, because of both the accumulation of uracil and
thymine and the reduced capacity to metabolize these
compounds and their analogues (Hayashi et al. 1996).
The molecular analysis of DHP deficiency that has been
reported here can be applied to cancer patients who will
be treated with pyrimidine analogues such as 5-FU.
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